View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
September 17, 2018updated 12 Jul 2022 1:12pm

Millendo Therapeutics starts Phase llb trial of nevanimibe for CAH

Millendo Therapeutics has begun a Phase llb clinical trial to investigate the efficacy and safety of nevanimibe for the treatment of patients with classic congenital adrenal hyperplasia (CAH).

Millendo Therapeutics has begun a Phase llb clinical trial to investigate the efficacy and safety of nevanimibe for the treatment of patients with classic congenital adrenal hyperplasia (CAH).

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

CAH is a rare inherited endocrine disease, which is the result of a genetic mutation preventing cortisol synthesis and is characterised by overgrowth of the adrenal glands, adrenal insufficiency, and other factors.

The new open-label, intra-subject, dose-escalation trial aims to include up to 24 adult CAH patients who are on the current standard of care, glucocorticoids.

During the course of the trial, patients will be treated with nevanimibe for 12 consecutive weeks starting with a dose of 1,000mg BID.

Depending on 17 hydroxyprogesterone (17-OHP) levels, the dose will be increased to 1,500mg BID or 2,000mg BID.

“Our Phase llb trial will explore longer durations of treatment and higher doses of nevanimibe with the objective of enabling more patients to achieve hormonal control.”

The trial’s primary objective is to evaluate the percentage of patients that achieve 17-OHP levels less than or equal to two times the upper limit of normal (ULN).

Its secondary objectives comprise evaluation of other adrenal hormones, including androgens.

Millendo Therapeutics president and CEO Julia Owens said: “We are encouraged by the positive Phase ll efficacy and safety results of nevanimibe that were presented at the Endocrine Society’s annual meeting in March, in which these data demonstrated reductions in key steroids and steroid precursors, including promising reductions in 17-OHP, a key measure of disease control.

“Our Phase llb trial will explore longer durations of treatment and higher doses of nevanimibe with the objective of enabling more patients to achieve hormonal control.”

Nevanimibe, formerly ATR-101, is an adrenal-selective inhibitor of acylCoA:cholesterol acyltransferase 1 (ACAT1) enzyme that catalyses the transformation of free cholesterol into cholesterol ester.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena